Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1991-06-04
1993-11-30
Lee, Lester L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 13, 514 14, 514 15, 514 16, 530307, 530324, 530325, 530326, 530327, 530328, 530329, C61K 3702, C07K 706, C07K 708, C07K 710
Patent
active
052665615
ABSTRACT:
Compounds and methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP], or biologically active sub-peptides thereof. Inhibitors include substituted peptides or sub-peptides of amylin or CGRP, cross-linked amylin and amylin agonists, synthetic amylin, anti-amylin receptor antibodies and anti-idiotype antibodies, and antibodies directed to amylin and amylin agonist active sites. Other antagonists include organic compounds which can be screened and assayed for anti-amylin effects by disclosed methods.
REFERENCES:
patent: 3530839 (1985-07-01), Evans
patent: 4687839 (1987-08-01), Kempe
patent: 4697002 (1987-09-01), Kempe
patent: 4720483 (1988-01-01), Janz
patent: 4736023 (1988-04-01), Evans
Westermark et al., Proc. Nat'l Acad. Sci. (USA). vol. 84, pp. 3881-3885.
Cooper et al. Proc. Nat'l Acad. Sci. (USA) (84), 8628-32.
Clark et al., Lancet Aug. 2, 1987.
Huse, et al., JAMA 262:2708-2713 (1989).
Cryer, et al., Diabetes 38:1193-1199 (1989).
Foord et al., Eur. J. Biochem. 170:373 (1987).
Sewell et al., Soc. Neurosci. Abs. 13:42 (1987).
Kimura et al., Neuropeptides 9:75 (1987).
Minvielle et al., FEBS Lett. 203:7 (1986).
Morris et al., Nature 308:746 (1984).
Craig et al., Biochem. Soc. Symp. 52:91 (1986).
Tippins et al., J. Hypertens., 4:5102 (1986).
Tippins et al., Biochem. Biophys. Res. Commun., 134:1306 (1981).
Holman et al., Peptides, 7:231 (1986).
Lenz et al., Gut, 26:550 (1985).
Westermark et al., Biochem. Biophys. Res. Commun. 140:827 (1986).
Westermark et al., Diabetologia, 30:887 (1987).
Westermark, et al., Proc. Nat. Sci. (USA), 84:3881 (1987).
Westermark et al., Am. J. Pathol., 127:414 (1987).
Cooper et al., Proc. Nat. Acad. Sci. (USA) 84:8628 (1987).
Cooper et al., Lancet 2:966 (1987).
Cooper Garth J. S.
Greene, Jr. Howard
Amylin Pharmaceuticals Inc.
Lee Lester L.
LandOfFree
Treatment of type 2 diabetes mellitus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of type 2 diabetes mellitus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of type 2 diabetes mellitus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2096329